Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vital NAD and DC vaccine for postoperative solid tumors
NCT06036355Phase 1Unknown
- Sponsor
- Shanghai Cell Therapy Group
- Start
- Sep 2023
- Primary completion
- Apr 2024
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nicotinamide mononucleotide and WT1/hTERT/Survivin-loaded dendritic cell vaccine in malignant solid tumor, sponsored by Shanghai Cell Therapy Group. Primary endpoints: Concentration of double antibodies in peripheral blood at 3 months, Concentration of nicotinamide mononucleotide in peripheral blood at 3 months and 8 more. Status: unknown.
02
Drugs
nicotinamide mononucleotideWT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT06036355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06036355.